Bellevue Group’s Audentes Therapeutics, Inc BOLD Stock Holding History

Bellevue Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,300	Closed	-$736K	–	231
2019 Q4	$736K	Sell	12,300 -1,417,304	-99%	-$53.2M	0.01%	155
2019 Q3	$40.2M	Buy	1,429,604 +60,000	+4%	+$2.05M	0.75%	39
2019 Q2	$51.9M	Buy	+1,369,604	New	+$52.6M	0.89%	32

Bellevue Group's BOLD Position: Q1 2020 in Review

Bellevue Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 12,300 shares — an estimated $736K sold.

Bellevue Group first reported a position in BOLD in Q2 2019 and held it in 3 quarters. The position peaked at $51.9M in Q2 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Bellevue Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Bellevue Group sold 12,300 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $736K.
Bellevue Group first reported a position in Audentes Therapeutics, Inc in Q2 2019 and held it in 3 quarters.
Bellevue Group's Audentes Therapeutics, Inc position peaked at $51.9M in Q2 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.